Analyst Ratings For NASDAQ:AERI – Aerie Pharmaceuticals (NASDAQ:AERI)
Today, Mizuho lowered its price target on NASDAQ:AERI – Aerie Pharmaceuticals (NASDAQ:AERI) to per share.
Some recent analyst ratings include
- 3/5/2018-Seaport Global Securities Reiterated Rating of Buy.
- 10/23/2017-Guggenheim initiated coverage with a Buy rating.
- 10/16/2017-Needham & Company LLC Reiterated Rating of Buy .
Recent Insider Trading Activity For NASDAQ:AERI – Aerie Pharmaceuticals (NASDAQ:AERI)
NASDAQ:AERI – Aerie Pharmaceuticals (NASDAQ:AERI) has insider ownership of 9.36% and institutional ownership of 96.93%.
- On 5/26/2017 Foresite Capital Fund Ii, L.P., Major Shareholder, sold 20,000 with an average share price of $55.95 per share and the total transaction amounting to $1,119,000.00.
- On 4/19/2017 Gerald D Cagle, Director, bought 2,000 with an average share price of $41.70 per share and the total transaction amounting to $83,400.00.
- On 2/15/2017 Geoffrey M Duyk, Director, sold 41,591 with an average share price of $46.63 per share and the total transaction amounting to $1,939,388.33.
- On 10/6/2016 Foresite Capital Fund Ii, L.P., Major Shareholder, sold 50,000 with an average share price of $40.34 per share and the total transaction amounting to $2,017,000.00.
- On 7/22/2016 Foresite Capital Fund Ii, L.P., Major Shareholder, bought 250,000 with an average share price of $17.50 per share and the total transaction amounting to $4,375,000.00.
- On 4/15/2015 Anand Mehra, Director, sold 425,000 with an average share price of $33.64 per share and the total transaction amounting to $14,297,000.00.
- On 1/8/2015 Lifesciences Ii L.P. Clarus, Major Shareholder, sold 175,000 with an average share price of $31.11 per share and the total transaction amounting to $5,444,250.00.
Recent Trading Activity for NASDAQ:AERI – Aerie Pharmaceuticals (NASDAQ:AERI)
Shares of NASDAQ:AERI – Aerie Pharmaceuticals closed the previous trading session at 51.60 up +0.40 0.78% with 51.900001525878906 shares trading hands.